U.S. Markets open in 2 hrs 38 mins
  • S&P Futures

    3,909.50
    -13.00 (-0.33%)
     
  • Dow Futures

    31,921.00
    +5.00 (+0.02%)
     
  • Nasdaq Futures

    13,169.50
    -132.50 (-1.00%)
     
  • Russell 2000 Futures

    2,291.50
    +6.40 (+0.28%)
     
  • Crude Oil

    63.26
    +0.04 (+0.06%)
     
  • Gold

    1,783.70
    -14.20 (-0.79%)
     
  • Silver

    28.02
    +0.09 (+0.33%)
     
  • EUR/USD

    1.2229
    +0.0061 (+0.5014%)
     
  • 10-Yr Bond

    1.3890
    0.0000 (0.00%)
     
  • Vix

    22.61
    -0.50 (-2.16%)
     
  • GBP/USD

    1.4134
    -0.0008 (-0.0537%)
     
  • USD/JPY

    106.1440
    +0.2620 (+0.2474%)
     
  • BTC-USD

    50,044.93
    -483.44 (-0.96%)
     
  • CMC Crypto 200

    1,001.65
    +6.99 (+0.70%)
     
  • FTSE 100

    6,679.35
    +20.38 (+0.31%)
     
  • Nikkei 225

    30,168.27
    +496.57 (+1.67%)
     

GW Pharma Receives EU Regulatory Agency Panel Backing For Epidiolex

  • Oops!
    Something went wrong.
    Please try again later.
Shanthi Rexaline
  • Oops!
    Something went wrong.
    Please try again later.

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) is inching closer to clearing another regulatory hurdle with respect to its cannabidiol drug Epidiolex, potentially opening up a market opportunity in Europe.

What Happened

The European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, issued a positive opinion on Epidiolex, the company said Friday.

The panel is recommending approval of Epidiolex for use as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome, or LGS — or Dravet syndrome in combination with clobazam — in patients two years and older.

Epidiolex is an oral solution containing highly purified cannabidiol with a novel mechanism of action. It has an Orphan Drug Designation from the EMA for treating seizures associated with LGS, Dravet syndrome and tuberculosis sclerosis complex.

The drug received FDA approval in June 2018 and launched commercially in the U.S. in November 2018

The product fetched GW Pharma sales of $33.5 million in the first quarter of 2019.

The company submitted the marketing authorization application to the EMA in December 2017, with the agency accepting it for review in February 2018.

"We are excited by the potential to bring patients and physicians a rigorously tested and evaluated cannabis-based medicine with a documented safety and efficacy profile, manufactured to the highest standards and approved by a medicines regulator," CEO Justin Grover said in a statement.

The CHMP opinion is positive for GWPH, Cantor Fitzgerald's Elemer Piros said in a Friday note.

The label inclusion of clobazam is unlikely to deter prescriptions in the EU, given the high unmet medical need and numerous positive Phase 3 data reported from GWPH, the analyst said.

"On the pricing front, GWPH does not believe pricing will be impacted, and remains confident on obtaining reimbursement in key markets."

Cantor Fitzgerald has an Overweight rating on GW Pharma with a $229 price target.

Benzinga's Cannabis Capital Conference heads to Detroit on Aug. 15 — click here to learn more!

What's Next

The European Commission is expected to a make a final decision on the regulatory application in about two months.

The approval, if it comes through, will authorize the company to market the drug in 28 EU nations, alongside Norway, Inceland and Liechtenstein.

GW Pharma shares were trading higher by 2.2% at $164.64 at the time of publication Friday.

Related Links:

GW Pharma's CBD Drug Epidiolex Could Secure Label Expansion Following Positive Trial Results

Morgan Stanley: DEA Likely To Reclassify GW Pharma's Cannabinoid Therapy For US Launch

Photo courtesy of GW Pharma.

Latest Ratings for GWPH

May 2019

Upgrades

Perform

Outperform

May 2019

Maintains

Overweight

Overweight

May 2019

Reiterates

Overweight

View More Analyst Ratings for GWPH
View the Latest Analyst Ratings

See more from Benzinga

© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.